Executive brief
Medical device cybersecurity is now a lifecycle requirement
Medical device cybersecurity has moved from technical best practice to a core part of product lifecycle control. Connected devices, software as a medical device, cloud-connected platforms, mobile applications, remote service models, open-source components, and supplier dependencies all create cybersecurity exposure that manufacturers need to manage before and after launch.
For FDA-regulated medical device companies, the regulatory signal is clear. FDA medical device cybersecurity expectations now connect secure product design, premarket submission content, software component visibility, and postmarket vulnerability management. Section 524B of the FD&C Act makes cybersecurity planning part of the evidence manufacturers need for certain cyber devices, including plans to monitor, identify, and address postmarket cybersecurity vulnerabilities.
USDM helps medical device manufacturers translate those expectations into practical execution: risk assessments, secure architecture, SBOM readiness, compliance evidence, vulnerability response planning, and ongoing governance that stands up across Quality, Regulatory, Engineering, IT, Security, and supplier oversight.
Software Bill of Materials readiness for medical devices
A Software Bill of Materials (SBOM) is a structured inventory of the software components used in a medical device, including proprietary code, open-source libraries, commercial software, off-the-shelf components, component versions, suppliers, and dependencies. For connected medical devices, SBOM readiness gives manufacturers the visibility needed to support FDA submission expectations, monitor vulnerabilities, govern suppliers, and respond when new cybersecurity issues emerge.
FDA cybersecurity guidance and the agency's medical device cybersecurity FAQs make SBOM evidence part of the larger cybersecurity lifecycle for cyber devices. The practical expectation is not a static PDF inventory. Teams need a maintained, machine-readable view of software components that can support standards such as SPDX or CycloneDX, connect to risk management, and stay current as software changes through patches, upgrades, bug fixes, supplier updates, or end-of-support events.
What SBOM readiness needs to prove
- Complete component visibility: inventory proprietary, open-source, commercial, and off-the-shelf software with names, versions, suppliers, and dependency relationships.
- Machine-readable evidence: maintain SBOM records in parseable formats that can support submission, security review, and ongoing analysis rather than manual spreadsheet reconciliation.
- Continuous vulnerability monitoring: compare software components against vulnerability sources such as the CISA Known Exploited Vulnerabilities Catalog and relevant CVE intelligence.
- Lifecycle change control: update the SBOM when patches, fixes, upgrades, supplier changes, or end-of-support conditions affect device software.
- Disclosure and response procedures: define how vulnerabilities will be assessed, escalated, communicated, patched, validated, and documented across patients, healthcare delivery organizations, regulators, and suppliers.
Global expectations are moving in the same direction. The NTIA SBOM framing document explains the value of software supply-chain transparency, while the FDA premarket cybersecurity guidance and FDA cybersecurity FAQs connect SBOM evidence to device cybersecurity expectations. USDM helps medical device companies assess whether their SBOM process is submission-ready, operationally maintainable, and strong enough to support postmarket cybersecurity obligations.
What FDA expects for premarket cybersecurity
Premarket cybersecurity is not a single attachment added near the end of a submission. It is the visible output of secure product development, threat modeling, architecture decisions, software component management, security testing, labeling, and lifecycle planning. FDA's current cybersecurity guidance describes the type of documentation FDA recommends for devices with cybersecurity risk and addresses Section 524B expectations for cyber devices.
For manufacturers, that means premarket cybersecurity evidence should connect intended use, architecture, interfaces, known risks, controls, testing rationale, update strategy, and postmarket monitoring. A device team should be able to explain how a medical device cyber threat was identified, evaluated, mitigated, tested, and monitored over time.
A practical FDA-ready cybersecurity evidence model
- Identify the cyber device scope: determine whether the product includes software, internet connectivity, or characteristics that could be vulnerable to cybersecurity threats.
- Build the threat model: document attack surfaces, trust boundaries, misuse scenarios, data flows, interfaces, and risk controls.
- Prepare SBOM evidence: maintain commercial, open-source, and off-the-shelf software component visibility in a format teams can govern over time.
- Validate security controls: connect testing, risk-based assurance, access control, encryption, logging, update mechanisms, and vulnerability handling to documented requirements.
- Plan postmarket monitoring: define how the organization will monitor, identify, assess, communicate, patch, and remediate vulnerabilities after release.
SBOM governance cannot stop at submission
Once a device is authorized, SBOM governance becomes part of the operating model. Hospitals and healthcare delivery organizations need timely component visibility when a zero-day vulnerability or exploited component emerges, and manufacturers need a defensible way to determine whether affected components exist in deployed products.
USDM helps teams treat SBOM as an operating control, not a static file. That includes defining ownership, component intake, supplier evidence, version tracking, vulnerability triage, risk acceptance, update documentation, and links to data integrity expectations so cybersecurity evidence remains accurate, attributable, reviewable, and available when teams need it.
Postmarket cybersecurity requires monitoring and response
Postmarket cybersecurity is where many device programs become operationally fragile. After a connected device enters the field, new vulnerabilities, software dependencies, operating environments, integrations, and threat intelligence can change the risk profile. A compliant program needs more than a launch package. It needs a working model for monitoring, triage, remediation, communication, and documented decision-making.
USDM supports postmarket programs by helping teams define vulnerability intake, severity assessment, coordinated disclosure, patch planning, validation impact, supplier escalation, and governance routines. That model aligns with broader continuous compliance expectations because cybersecurity posture changes as products, platforms, and threats change.
IT risk assessments for medical device environments
USDM's IT risk assessments identify potential vulnerabilities across systems, networks, cloud environments, suppliers, and regulated workflows. The goal is not just to produce a risk register. The goal is to give medical device leaders a prioritized view of cybersecurity risk, compliance exposure, and the controls needed to reduce operational and regulatory risk.
Our approach evaluates the current security posture, maps gaps to relevant FDA and global expectations, and turns findings into mitigation actions. That includes product-adjacent systems, quality platforms, clinical and regulatory data environments, manufacturing systems, and the infrastructure that supports connected devices. Related USDM thinking on cybersecurity standards in life sciences reinforces the same principle: controls need to match the regulated context, not generic enterprise checklists.
Secure infrastructure design for connected products
Secure infrastructure design helps medical device manufacturers build compliance-first architectures around encryption, access control, logging, monitoring, segmentation, backup, disaster recovery, and validated change management. The infrastructure supporting connected products must protect sensitive data while allowing teams to operate, patch, investigate, and scale.
USDM brings deep experience with secure cloud and GxP environments, including the control discipline shown in USDM Designs AWS Data Lake to Standardize GxP Data Management Processes. For medical device cybersecurity, that same architecture mindset helps teams protect clinical, quality, regulatory, and device-related data without losing auditability.
Cybersecurity compliance regulations and audit readiness
Medical device cybersecurity programs need to align with FDA expectations and broader global standards without turning compliance into paperwork theater. USDM helps teams prepare evidence for FDA medical device cybersecurity, premarket cybersecurity, SBOM governance, postmarket cybersecurity, quality system procedures, and audit-ready risk management.
The USDM white paper Cybersecurity Requirements for Medical Devices is a practical starting point for teams building or maturing this program. For organizations also managing vendors, suppliers, cloud providers, and service partners, Building Your Trusted Partner Ecosystem connects device cybersecurity to the broader partner ecosystem that can influence product and operational risk.
vCISO support for medical device manufacturers
Many medical device companies need cybersecurity leadership before they are ready to hire a full-time CISO. USDM's vCISO for life sciences engagements provide strategic cybersecurity leadership, risk governance, compliance alignment, board-ready communication, and oversight for ongoing assessments.
A vCISO model can help manufacturers prioritize investment, respond to regulatory expectations, coordinate cross-functional ownership, manage third-party risk, and keep cybersecurity aligned with business objectives. It is especially useful when teams need to mature quickly before a submission, acquisition, platform expansion, or postmarket security event.
How USDM helps medical device companies move forward
USDM combines medical device regulatory understanding, cybersecurity experience, validation discipline, secure infrastructure design, and life sciences operating knowledge. That combination matters because cybersecurity decisions do not live only in Security. They affect submission readiness, product lifecycle management, quality procedures, supplier governance, data integrity, and patient safety.
Start with a focused medical device cybersecurity assessment, a premarket evidence gap review, an SBOM readiness review, or a vCISO-led roadmap. USDM can help define the current state, prioritize remediation, document the evidence, and build the operating model needed to keep connected products secure and compliant over time.
Need a practical next step? Download the Medical Device Manufacturers datasheet or contact USDM to map your medical device cybersecurity roadmap.
